Madrigal’s Maestro result puts the focus on Nash
Resmetirom’s first pivotal liver disease study reminds the markets about the third quarter’s Nash readout, but investors wanted more.
Genfit rises from the ashes of elafibranor
Ipsen hopes to draw a line under its earlier deal-making snafu with a bet on Genfit, and investors have just over a year’s wait for the proof.
One victory for biopharma over the coronavirus in 2020
A rollercoaster year for biopharma ended with investors firmly deciding that the pandemic was an opportunity, not a threat.
Shedding light on Intercept’s opaque disclosure
Intercept’s woes have continued as a possible new liver toxicity signal was buried in a regulatory filing. What could this mean?
Has 2020 been a big year for regulatory knockbacks?
An analysis of FDA complete response letters does not reveal a big uptick – but the year is not over yet.
The Cymabay recovery continues
Encouraging cholangitis data follows the lifting of a clinical hold on Cymabay’s seladelpar, signalling a way forward for a project that looked finished.
Biopharma shares shake off the pandemic
Global drug stocks enthusiastically joined the recovery on the financial markets in the second quarter, more than offsetting earlier declines.
